Advanced glycation end products and diabetic complications

Bibliography

• AMOS AF, MCCARTY DJ, ZIMMET P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. (1997) 14\(Suppl. 5):S1–S85.
   Google Scholar
• DONAHUE RP, ORCHARD TJ: Diabetes mellitus and microvascular complications. An epidemiological perspective. Diabetes Care (1992) 15(9):1141–1155.
   PubMed Web of Science ®Google Scholar
• UKPDS: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 352(9131):854–865.
   PubMed Web of Science ®Google Scholar
• DCCT: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes (1993) 46(2):271–286.
   Google Scholar
• COOPER ME: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia (2001) 44(11):1957–1972.
   PubMed Web of Science ®Google Scholar
• COOPER ME, GILBERT RE, JERUMS G: Diabetic vascular complications. Clin. Exp. Pharmacol Physiol (1997) 24(9-10):770–775.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M: Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 414(6865):813–820.
   PubMed Web of Science ®Google Scholar
• •Review of the central importance of hyperglycaemia-mediated generation of superoxide as a phenomenon that may unify a number of pathogenic mechanisms during diabetic complications. Experimental data published by Nishikawa eta]. Nature (2000) 404(6779):787–790.
   Google Scholar
• MONNIER VM, BAUTISTA 0, KENNY D et al.: Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of Type 1 diabetes: relevance of glycated collagen products versus HbA lc as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes (1999) 48(4):870–880.
   Google Scholar
• •Definitively shows that AGEs accumulation and crosslinking correlate with intensive glycaemic control in the DCCT patients.
   Google Scholar
• BAYNES JVV, MONNIER VM: The Maillard reaction in aging, diabetes, and nutrition. In Progress M clinical biological research. Vol. 304. Alan R. Liss., New York (1989):1–410.
   Google Scholar
• AHMED MU, THORPE SR, BAYNES JW: Identification of carboxymethyllysine as a degradation product of fructoselysine in glycated protein. Biol. Chem. (1986) 261:8816–8821.
   Google Scholar
• •An identification of CML as an important glycoxidation product. This work lead to may in vivo studies and suggested the pathophysiological significance of oxidative processes in AGE formation.
   Google Scholar
• WELLS-KNECHT MC, THORPE SR, BAYNES JW: Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry (1995) 34:15134–15141.
   PubMed Web of Science ®Google Scholar
• THORNALLEY PJ, LANGBORG A, MINHAS HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochemistry (1999) 344:109–116.
   Google Scholar
• THORNALLEY PJ: The glyoxalase system:new developments towards characterisation of a metabolic pathway fundamental to biological life. Biochemistry' (1990) 269:1–11.
   Google Scholar
• NJOROGE FG, SAYRE LM, MONNIER VM: Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr: Res. (1987) 167:211–220.
   PubMed Web of Science ®Google Scholar
• MIYATA S, MONNIER VM: Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. Clin. Investig. (1992) 89:1102–1112.
   Google Scholar
• FRYE EB, DEGENHARDTTP, THORPE SR, BAYNES JW: Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J. Biol. Chem. (1998) 273(30):18714–18719.
   Google Scholar
• OBAYASHI H, NAKANO K., SHIGETA H et al.: Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. Biochem. Biophys. Res. Commun. (1996) 226(1):37–41.
   Google Scholar
• ONO Y, AOKI S OHNISHI K et al: Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res. Clin. Piaci (1998) 41(2):131–137.
   PubMed Web of Science ®Google Scholar
• BAYNES JW, THORPE SR: Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. (2000) 28(12):1708–1716.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the biological implications for a spectrum of advanced glycation reactions.
   Google Scholar
• CERAMI C, FOUNDS H, NICHOLL I et al.: Tobacco smoke is a source of toxic reactive glycation products. Proc. Nat. Acad. Sci. USA (1997) 94:15–20.
   PubMedGoogle Scholar
• •Liberation of highly reactive AGE fragments may be released during tobacco combustion and enter the bloodstream of smokers.
   Google Scholar
• NICHOLL ID,STITT AW, MOORE JE, RITCHIE AJ, ARCHER DB, BUCALA R: Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Ma Med (1998) 4(9):594–601.
   PubMed Web of Science ®Google Scholar
• KOSCHINSKY T, HE CJ, MITSUHASHI T et al.: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Nat. Acad. Sci. USA (1997) 94(12):6474–6479.
   PubMed Web of Science ®Google Scholar
• •AGEs formed during food preparation may enter the bloodstream as reactive AGE-peptides.
   Google Scholar
• HE C, S.J., MITSUHASHI T, VLASSARAH: Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes (1999) 48(6):1308–1315.
   PubMed Web of Science ®Google Scholar
• BUCALA R, MODEL P, CERAMI A: Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc. Nat. Acad. Sci. USA (1984) 81:105–109.
   PubMed Web of Science ®Google Scholar
• LEDESMA MD, BONAY P, COLACO C, AVILA J: Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. (1994) 269(34):21614–21619.
   PubMed Web of Science ®Google Scholar
• HOWARD EW, BENTON R, AHERN-MOORE J, TOMASEK JJ: Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp. Cell Res. (1996) 228(1):132–137.
   PubMed Web of Science ®Google Scholar
• PAGET C, LECOMTE M, RUGGIERO D, WIERNSPERGER N, LAGARDE M: Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radic. Biol. Med. (1998) 25(1):121–129.
   PubMed Web of Science ®Google Scholar
• GIARDINO I, EDELSTEIN D, BROWNLEE M: Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. .1. Clin. Investig. (1994) 94:489–496.
   Google Scholar
• •First to show a major role for intracellular AGEs in vascular cells.
   Google Scholar
• ABDEL-WAHAB YH, O'HARTE FP, RATCLIFF H, MCCLENAGHAN NH, BARNETT CR, FLATT PR: Glycation of insulin in the islets of Langerhans of normal and diabetic animals. Diabetes (1996) 45(11):1489–1496.
   PubMed Web of Science ®Google Scholar
• VLASSARA H: The AGE-receptor in the pathogenesis of diabetic complications. Diabet. Metab. Res. Rev. (2001) 17(6):436–443.
   PubMed Web of Science ®Google Scholar
• SCHMIDT AM,YAN SD, YAN SF, STERN DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta (2000) 1498(2-3):99–111.
   PubMed Web of Science ®Google Scholar
• SANO H, NAGAI R, MATSUMOTO K, HORIUCHI S: Receptors for proteins modified by advanced glycation endproducts (AGE)-their functional role in atherosclerosis. Mech. Ageing Dev (1999) 107(3):333–346.
   PubMed Web of Science ®Google Scholar
• SCHMIDT AM HORI 0, BRETT J, YAN SD, WAUTIER JL, STERN D: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosclec Thromb. (1994) 14(10):1521–1528.
   Google Scholar
• Li YM, WD, MITSUHASHI T, GILMORE R etMolecular identity and tissuedistribution of advanced glycation endproduct receptors. Relationship of p60 to OST 48 and 80KH membrane proteins. Proc. Nat. Acad. Sci. USA (1996) 93:11047–11052.
   Google Scholar
• STITT AW, HE C, VLASSARA H: Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem. Biophys. Res. Commun. (1999) 256(3):549–556.
   PubMed Web of Science ®Google Scholar
• STITT AW, BURKE GA, CHEN F, MCMULLEN CB, VLASSARA H: Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. FASEB J. (2000) 14(15):2390–2393.
   PubMed Web of Science ®Google Scholar
• HORIUCHI S, HIGASHI T, IKEDA K et al: Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes (1996) 45\(Suppl. 3):S73–S76.
   Google Scholar
• MENE P, PASCALE C, TETI A, BERNARDINI S, CINOTTI GA, PUGLIESE F: Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. J. Am. Soc. Nephrol (1999) 10(7):1478–1486.
   PubMed Web of Science ®Google Scholar
• SCIVITTARO V, GANZ MB, WEISS MF: AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am. I Physic]. Renal Physiol (2000) 278(4):F676–F683.
   PubMed Web of Science ®Google Scholar
• HUANG JS, GUH JY, HUNG WC et al: Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochem. J. (1999) 342(Pt 1):231–238.
   PubMedGoogle Scholar
• DEORA AA, WI NT, VANHAESEBROECK B, LANDER HM: A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 3 kinase to Ras by redox stress. J. Biol. Chem. (1998) 273(45):29923–29928.
   Google Scholar
• LANDER H, TAURAS JM, OGISTE JS, HORI 0, MOSS RA, SCHMIDT AM: Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Chem. (1997) 272(28):17810–17814.
   Google Scholar
• SIMM A, MUNCH G, SEIF F et al.: Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1. FEBS Lett. (1997) 410(2-3):481–484.
   PubMed Web of Science ®Google Scholar
• BIERHAUS A, SCHIEKOFER S, SCHWANINGER M et al.: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes (2001) 50(12):2792–2808.
   PubMed Web of Science ®Google Scholar
• HUDSON BI, STICKLAND MH, FUTERS TS, GRANT PJ: Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes (2001) 50(6):1505–1511.
   PubMed Web of Science ®Google Scholar
• POIRIER 0, NICAUD V, VIONNET N: Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in Type 1 diabetic patients. Diabetes (2001) 50(5):1214–1218.
   Google Scholar
• PULKKINEN A, VIITANEN L, KAREINEN A, LEHTO S, LAAKSO M: Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with Type 2 diabetes. Diabetes Care (2000) 23(6):864.
   PubMed Web of Science ®Google Scholar
• KANKOVA K, MAROVA I, ZAHEJSKY J: Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism (2001) 50(10):1152–1160.
   PubMed Web of Science ®Google Scholar
• KANKOVA K, ZAHEJSKY J, MAROVA I et al.: Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. I Diabetes Complications (2001) 15(4):185–192.
   PubMed Web of Science ®Google Scholar
• TOOKE J: Possible pathophysiological mechanisms for diabetic angiopathy in Type 2 diabetes. Diabetes Complications (2000) 14(4):197–200.
   PubMed Web of Science ®Google Scholar
• JOHNSON PC, BRENDEL K, MEEZAN E: Thickened cerebral cortical capillary basement membranes in diabetics. Arch. Pathol Lab. Med. (1982) 106(5):214–217.
   PubMed Web of Science ®Google Scholar
• JUNKER U, JAGGI C, BESTETTI G, ROSSI GL: Basement membrane of hypothalamus and cortex capillaries from normotensive and spontaneously hypertensive rats with streptozotocin-induced diabetes. Acta Neuropathol (Berlin) (1985) 65(3-4):202–208.
   PubMed Web of Science ®Google Scholar
• KERN TS, ENGERMAN RL: Capillary lesions develop in retina rather than cerebral cortex in diabetes and experimental galactosemia. Arch. Ophthalmol (1996) 114(3):306–310.
   PubMed Web of Science ®Google Scholar
• •Shows preferential susceptibility of the retinal capillaries when compared to a closely-related microvascular bed.
   Google Scholar
• KROLEWSKI AS, CANESSA M, WARRAM JH et al.: Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl. J. Med. (1988) 318(3):140–145.
   PubMed Web of Science ®Google Scholar
• FIORETTO P, MAUER M, BROCCO E et al.: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia (1996) 39(12):1569–1576.
   PubMed Web of Science ®Google Scholar
• OSTERBY R: Structural changes in the diabetic kidney. Clin. Endocrinol Metab. (1986) 15(4):733–751.
   PubMedGoogle Scholar
• GILBERT RE, COOPER ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. (1999) 56(5):1627–1637.
   Google Scholar
• SOULIS T, COOPER ME, VRANES D, BUCALA R, JERUMS G: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int. (1996) 50(2):627–634.
   PubMed Web of Science ®Google Scholar
• SEBEKOVA K, PODRACKA L, BLAZICEK P, SYROVA D, HEIDLAND A, SCHINZEL R: Plasma levels of advanced glycation end products in children with renal disease. Pediam Nephrol. (2001) 16(12):1105–1112.
   PubMed Web of Science ®Google Scholar
• SEBEKOVA K, KUPCOVA V, SCHINZEL R, HEIDLAND A: Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J. Hepatol. (2002) 36(1):66–71.
   PubMed Web of Science ®Google Scholar
• MIYATA T, ISHIGURO N, YASUDA Y et al.: Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem. Biophys. Res. Commun. (1998) 244(1):45–49.
   PubMed Web of Science ®Google Scholar
• GUGLIUCCI A, BENDAYAN M: Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry. Histochem. Cytochem. (1995) 43(6):591–600.
   PubMed Web of Science ®Google Scholar
• YANG CW, VLASSARA H, PETEN EP, HE CJ, STRIKER GE, STRIKER LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc. Nati Acad. ScL USA (1994) 91(20):9436–9440.
   PubMed Web of Science ®Google Scholar
• VLASSARA H, STRIKER LJ, TEICHBERG S, FUH H, LI YM, STEFFES M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl Acad. Sci. USA (1994) 91(24):11704–11708.
   PubMed Web of Science ®Google Scholar
• •AGEs appear to promote advanced stages of diabetic-like nephropathy independently of hyperglycaemia.
   Google Scholar
• SOULIS T, SASTRA S, THALLAS V et al.: A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia (1999) 42(4):472–479.
   PubMed Web of Science ®Google Scholar
• KELLY DJ, GILBERT RE, COX AJ, SOULIS T, JERUMS G, COOPER ME: Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. I Am. Soc. Nephrol. (2001) 12(10):2098–2107.
   PubMed Web of Science ®Google Scholar
• BACH LA, DEAN R, YOUSSEF S, COOPER ME: Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrol. Dial. Transplant. (2000) 15(3):347–354.
   PubMed Web of Science ®Google Scholar
• OSICKA TM, YU Y, LEE V, PANAGIOTOPOULOS S, KEMP BE, JERUMS G: Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin. ScL (Lond) (2001) 100(3):249–257.
   PubMed Web of Science ®Google Scholar
• TSUJI H, IEHARA N, ROMEO G et al: Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem. Biophys. Res. Commun. (1998) 245(2):583–588.
   PubMed Web of Science ®Google Scholar
• PUGLIESE G, PRICCI F, ROMEO G et al: Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes (1997) 46(11):1881–1887.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO Y, KATO I, DOI T et al.: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invert. (2001) 108(2):261–268.
   PubMed Web of Science ®Google Scholar
• ••Diabetic mice overexpressing RAGE showenhanced renal lesions when compared with diabetic littermates lacking the RAGE transgene.
   Google Scholar
• LI YM, MITSUHASHI T, WOJCIECHOWICZ D et al.: Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. USA (1996) 93(20):11047–11052.
   PubMed Web of Science ®Google Scholar
• STITT AW, HE C, VLASSARA H: Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biocliem. Biophys. Res. Commun. (1999) 256(3):549–556.
   PubMed Web of Science ®Google Scholar
• PUGLIESE G, PRICCI F, IACOBINI C et al: Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB. (2001) 15(13):2471–2479.
   PubMed Web of Science ®Google Scholar
• •First paper to show a possible interaction between distinct AGE receptors (RAGE and galectin-3) with implications for diabetic vascular complications.
   Google Scholar
• MIYATA T, FU MX, KUROKAWA K, VAN YPERSELE DE STRIHOU C, THORPE SR, BAYNES JW: Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int. (1998) 54(4):1290–1295.
   Google Scholar
• MAKITA Z, YANAGISAWA K, KUWAJIMA S et al.: Advanced glycation endproducts and diabetic nephropathy. Diabetes Complications (1995) 9(4):265–268.
   PubMed Web of Science ®Google Scholar
• GUGLIUCCI A, BENDAYAN M: Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia (1996) 39(2):149–160.
   PubMed Web of Science ®Google Scholar
• MIYATA T, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int. (2000) 76 (Suppl.):S120–S125.
   Google Scholar
• RAJ DS, CHOUDHURY D, WELBOURNE TC, LEVI M: Advanced glycation end products: a Nephrologist's perspective. Am. J. Kidney Dis. (2000) 35(3):365–380.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, GARDNER TW, KING GL et al.: Diabetic retinopathy. Diabetes Care (1998) 21(1):143–156.
   PubMed Web of Science ®Google Scholar
• KLEIN R, KLEIN BE, MOSS SE, CRUICKSHANKS KJ et al: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in Type 1 diabetes. Ophthalmology (1998) 105(10):1801–1815.
   Google Scholar
• ANTONETTI DA, LIETH E, BARBER AJ, GARDNER TW: Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin. Ophthalmol. (1999) 14(4):240–248.
   PubMedGoogle Scholar
• STITT AW, ANDERSON HR, GARDINER TA, ARCHER DB: Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br. J. Oplithalmol (1994) 78(2):133–137.
   PubMed Web of Science ®Google Scholar
• GARDINER TA, STITT AW, ANDERSON HR, ARCHER DB: Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs. Br. J. Oplithalmol (1994) 78(1):54–60.
   PubMed Web of Science ®Google Scholar
• KERN TS, ENGERMAN RL: Vascular lesions in diabetes are distributed non-uniformly within the retina. Exp. Eye Res. (1995) 60(5):545–549.
   PubMed Web of Science ®Google Scholar
• STITT AW, GARDINER TA, ARCHER DB: Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br. J. Oplithalmol (1995) 79(4):362–367.
   PubMed Web of Science ®Google Scholar
• SHARMA NK, GARDINER TA, ARCHER DB: A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. Am. J. Oplithalmol. (1985) 100(1):51–60.
   PubMed Web of Science ®Google Scholar
• •Shows a specific turnover of endothelial cells in the diabetic retina and a much lower replicative capacity for the pericyte.
   Google Scholar
• SCHMETTERER L, WOLZT M: Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia (1999) 42(4):387–405.
   PubMed Web of Science ®Google Scholar
• KOHNER EM, PATEL V, RASSAM SM: Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes (1995) 44(6):603–607.
   PubMed Web of Science ®Google Scholar
• STITT AW, CHAKRAVARTHY U, ANCHER DB, GARDINER TA: Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation. Diabetologia (1995) 38(11):1271–1275.
   PubMed Web of Science ®Google Scholar
• GARDINER TA, STITT AW, ARCHER DB: Retinal vascular endothelial cell endocytosis increases in early diabetes. Lab. Invest. (1995) 72(4):439–444.
   PubMed Web of Science ®Google Scholar
• ENGERMAN RL, KERN TS: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes (1987) 36(7):808–812.
   PubMed Web of Science ®Google Scholar
• ••Long-term study that demonstrates theconcept of hyperglycaemic memory in the diabetic dog, an excellent model of pre-proliferative vascular lesions.
   Google Scholar
• SU EN, ALDER VA, YU DY, YU PK, CRINGLE SJ, YOGESAN K: Continued progression of retinopathy despite spontaneous recovery to normoglycemia in a long-term study of streptozotocin-induced diabetes in rats. Craefes Arch. Clin. Exp. Oplithalmol (2000) 238(2):163–173.
   PubMed Web of Science ®Google Scholar
• STITT AW, LI YM, GARDINER TA, BUCCALA R, ARCHER DB, VLASSARA H: Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am.j PathoL (1997) 150(2):523–531.
   PubMed Web of Science ®Google Scholar
• •This paper shows that AGEs accumulate in the diabetic retinal microvasculature, especially in the pericyte.
   Google Scholar
• HAMMES HP, BROWNLEE M, LIN J, SCHLEICHER E, BRETZEL RG: Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia (1999) 42(5):603–607.
   PubMed Web of Science ®Google Scholar
• SCHALKWIJK CG, LIGTVOET N, TWAALFHOVEN H et al.: Amadori albumin in Type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes (1999) 48(12)2446–2453.
   Google Scholar
• CHIARELLI F, DE MARTINO M, MEZZETTI A et al.: Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J. Pediatr. (1999) 134(4):486–491.
   PubMed Web of Science ®Google Scholar
• HAMMES HP, WELLENSIEK B, KLOTING I, SICKEL E, BRETZEL RG. BROWNLEE M: The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia (1998) 41(2):165–170.
   Google Scholar
• STITT AW, BHADURI T, MCMULLEN CB, GARDINER TA, ARCHER DB: Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. MoL Cell Biol. Res. Commun. (2000) 3(6):380–388.
   PubMedGoogle Scholar
• MCMULLEN TB et al.: A Modulatory Role for Advanced Glycation End-Products (AGEs) in Retinal Microvascular Leukostasis. Invest. OplitlialmoL Vis. Sci. (2002) 43:1348 (Abstract).
   Google Scholar
• BONNARDEL-PHU E, WAUTIER JL, SCHMIDT AM, AVILA C, VICAUT E: Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes (1999) 48(10):2052–2058.
   PubMed Web of Science ®Google Scholar
• HAMMES HP, MARTINS, FEDERLIN K, GEISEN K, BROWNLEE M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Nat. Acad. Sci. USA (1991) 88:11555–11558.
   PubMed Web of Science ®Google Scholar
• •First study to show that aminoguanidine may prevent retinopathy in a diabetic animal model. Questions still remain if this effect was due to AGE-inhibition or other non specific effects of this drug.
   Google Scholar
• KERN TS, ENGERMAN RL: Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes (2001) 50(7):1636–1642.
   PubMed Web of Science ®Google Scholar
• KERN TS, TANG J, MIZUTANI Met al.: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest. Oplithalmol Vis. Sci. (2000) 41(12):3972–3978.
   Google Scholar
• AGARDH E, HULTBERG B, AGARDH C: Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Curt Eye Res. (2000) 21(1):543–549.
   PubMed Web of Science ®Google Scholar
• ROUFAIL E, SOULIS T, BOEL E, COOPER ME, REES S: Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Diabetologia (1998) 41(12):1419–1425.
   PubMed Web of Science ®Google Scholar
• HAMMES HP, ALT SS, UHLMANN M et al.: Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia (1995) 38(3)269–273.
   Google Scholar
• HAMMES HP, STRODTER D, WEISS A, BRETZEL RG, FEDERLIN K, BROWNLEE M: Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia (1995) 38(6):656–660.
   PubMed Web of Science ®Google Scholar
• STITT AW et al.: The novel advanced glycation endproduct (AGE) inhibitor pyridoxamine prevents retinal vascular death during diabetic retinopathy. Diabetes (2002) (In Press).
   Google Scholar
• PADAYATTI PS, JIANG C, GLOMB MA, UCHIDA K, NAGARAJ RH: High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells. Curr: Eye Res (2001) 23(2):106–115.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTHY U, HAYES RG, STITT AW, MCAULEY E, ARCHER DB: Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes (1998) 47(6):945–952.
   PubMed Web of Science ®Google Scholar
• YAMAGISHI S, AMANO S, INAGAKI Y et al.: Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun. (2002) 290(3):973–978.
   PubMed Web of Science ®Google Scholar
• YAMAGISHI S, FUJIMORI H, YONEKURA H, TANAKA N, YAMAMOTO H: Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem. Biophys. Res. Commun. (1999) 258(2):353–357.
   PubMed Web of Science ®Google Scholar
• RUGGIERO-LOPEZ D, RELLIER N, LECOMTE M, LAGARDE M, WIERNSPERGER N: Growth modulation of retinal microvascular cells by early and advanced glycation products. Diabetes Res. Clin. Piaci (1997) 34(3):135–142.
   PubMed Web of Science ®Google Scholar
• RELLIER N, RUGGIERO-LOPEZ D, LECOMTE M, LAGARDE M, WIERNSPERGER N: In vitro and in vivo alterations of enzymatic glycosylation in diabetes. Life Sci. (1999) 64(17):1571–1583.
   PubMed Web of Science ®Google Scholar
• CHIBBER R, MOLINATTI PA, ROSATTO N, LAMBOURNE B, KOHNER EM: Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia (1997) 40(2):156–164.
   PubMed Web of Science ®Google Scholar
• LU M, KUROKI M, AMANO S et al: Advanced glycation end products increase retinal vascular endothelial growth factor expression. Clin. Invest. (1998) 101(6):1219–1224.
   Google Scholar
• HIRATA C, NAKANO K, NAKAMURA N et al.: Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem. Biophys. Res. Commun. (1997) 236(3):712–715.
   PubMed Web of Science ®Google Scholar
• YAMAGISHI S, YONEKURA H, YAMAMOTO Y et al.: Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. Biol. Chem. (1997) 272(13):8723–8730.
   Google Scholar
• VINIK Al, PARK TS, STANSBERRY KB, PITTENGER GL: Diabetic neuropathies. Diabetologia (2000) 43(8):957–973.
   PubMed Web of Science ®Google Scholar
• CAMERON NE, EATON SE, COTTER MA, TESFAYE S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia (2001) 44(11):1973–1988.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO K, NISHIZAWA Y, HORIUCHI S et al.: Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia (1997) 40(12):1380–1387.
   PubMed Web of Science ®Google Scholar
• RYLE C, LEOW CK, DONAGHY M: Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus. Muscle Nerve (1997) 20(5):577–584.
   PubMed Web of Science ®Google Scholar
• HAMMES HP, WEISS A, HESS S et al.: Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab. Invest (1996) 75 (3):325–338.
   PubMed Web of Science ®Google Scholar
• PAUL RG, BAILEY AJ: The effect of advanced glycation end-product formation upon cell-matrix interactions. Int.' Biochem. Cell Biol. (1999) 31(6):653–660.
   PubMed Web of Science ®Google Scholar
• CAMERON NE, COTTER MA, DINES K, LOVE A et al.: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia (1992) 35 (10946–950.
   Google Scholar
• TANIWAKI H, SHOJI T, EMOTO M et al.: Femoral artery wall thickness and stiffness in evaluation of peripheral vascular disease in Type 2 diabetes mellitus. Atherosclerosis (2001) 158(1):207–214.
   PubMed Web of Science ®Google Scholar
• ROMNEY JS, LEWANCZUK RZ: Vascular compliance is reduced in the early stages of Type 1 diabetes. Diabetes Care (2001) 24(12):2102–2106.
   PubMed Web of Science ®Google Scholar
• JANDELEIT-DAHM K, COOPER ME: Hypertension and diabetes. Curr: Opin. Nephrol Hypertens. (2002) 11(2):221–228.
   PubMed Web of Science ®Google Scholar
• AHLGREN AR, S.G., WOLLMER P, SONESSON B, LANNE T: Increased aortic stiffness in women with Type 1 diabetes mellitus is associated with diabetes duration and autonomic nerve function. Diabet. Med (1999) 16(4):291–297.
   PubMed Web of Science ®Google Scholar
• COOPER ME, BONNET F, OLDFIELD M, JANDELEIT-DAHM K: Mechanisms of diabetic vasculopathy: an overview. Am. Hypertens. (2001) 14(5 Pt 1):475–486.
   Google Scholar
• STITT AW, BUCALA R, VLASSARA H: Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann. NY Acad. Sci. (1997) 811:115-127; discussion 127–129.
   Google Scholar
• ULRICH P, CERAMI A: Protein glycation, diabetes, and aging. Recent Frog. Horm. Res. (2001) 56:1–21.
   PubMedGoogle Scholar
• BRUEL A, OXLUND H: Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age. Atherosclerosis (1996) 127(2):155–165.
   PubMed Web of Science ®Google Scholar
• BERG TJ, SNORGAARD 0, FABER J et al.: Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with Type 1 diabetes. Diabetes Care (1999) 22(7):1186–1190.
   Google Scholar
• KASS DA, SHAPIRO EP, KAWAGUCHI M et al.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation (2001) 104(13):1464–1470.
   PubMed Web of Science ®Google Scholar
• CANTINI C, KIEFFER P, CORMAN B, LIMINANA P, ATKINSON J, LARTAUD-IDJOUADIENE I: Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertension (2001) 38(4):943–948.
   PubMed Web of Science ®Google Scholar
• CORMAN B, DURIEZ M, POITEVIN P et al.: Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc. Natl Acad. Sci. USA (1998) 95(3):1301–1306.
   PubMed Web of Science ®Google Scholar
• PANAGIOTOPOULOS S, O'BRIEN RC, BUCALA R, COOPER ME, JERUMS G: Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis (1998) 136(1):125–131.
   PubMed Web of Science ®Google Scholar
• HORIUCHI S, HIGASHI T, IKEDA K et al.: Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes (1996) 45\(Suppl. 3):573–576.
   Google Scholar
• SAKATA N, IMANAGA Y, MENG J et al: Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis (1998) 141(1):61–75.
   PubMed Web of Science ®Google Scholar
• HATTORI Y, SUZUKI M, HOTTORI S, KASAI K: Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension (2002) 39(1):22–28.
   PubMed Web of Science ®Google Scholar
• STITT AW, HE C, FRIEDMAN S et al: Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Ma Med. (1997) 3(9):617–627.
   Google Scholar
• KUME S, TAKEYA M, MORI T et Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am. Pathol (1995) 147(3):654–667.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M, PONGOR S, CERAMI A: Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen. Role in the in situ formation of immune complexes. J. Exp. Med. (1983) 158(5):1739–1744.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M, VLASSARA H, CERAMI A: Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes (1985) 34(9):938–941.
   PubMed Web of Science ®Google Scholar
• ESPOSITO C, FASOLI G, PLATI AR etal.: Long-term exposure to high glucose up-regulates VCAM-induced endothelial cell adhesiveness to PBMC. Kidney Int. (2001) 59(5):1842–1849.
   Google Scholar
• SCHMIDT AM, HORI 0, CHEN JX et al: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. Clin. Invest. (1995) 96(3):1395–1403.
   PubMed Web of Science ®Google Scholar
• SANO H, NAGAI R, MATSUMOTO K, HORIUCHI S: Receptors for proteins modified by advanced glycation endproducts (AGE)-their functional role in atherosclerosis. Mech. Ageing Dev (1999) 107(3):333–346.
   PubMed Web of Science ®Google Scholar
• SCHMIDT AM, YAN SD, WAUTIERJL, STERN D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. (1999) 84(5):489–497.
   PubMed Web of Science ®Google Scholar
• BUCALA R, MITCHELL R, ARNOLD K, INNERARITY T, VLASSARA H, CERAMI A: Identification of the major site of apolipoprotein B modification by advanced glycation endproducts blocking uptake by the low density lipoprotein receptor. J. Biol. Chem. (1995) 270:10828–10832.
   PubMed Web of Science ®Google Scholar
• ••This study shows that AGE-modification ofthe ApoB component of LDL may influence its recognition by the LDL receptor.
   Google Scholar
• TOSHIMA S, HASEGAWA A, KURABAYASHI M et al.: Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. (2000) 20(10):2243–2247.
   PubMed Web of Science ®Google Scholar
• BUCALA R, MAKITA Z, VEGA G et al: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl Acad. Sci. USA (1994) 91(20):9441–9445.
   PubMed Web of Science ®Google Scholar
• LALLA E, LAMSTER IB, SCHMIDT AM: Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes. Ann. Periodontol (1998) 3(1):13–19.
   PubMedGoogle Scholar
• LALLA E, LAMSTER IB, STERN DM, SCHMIDT AM: Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. Ann. Periodontol (2001) 6(1):113–118.
   PubMedGoogle Scholar
• SELL DR, KLEINMAN NR, MONNIER VM: Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice. FASEB J. (2000) 14(1):145–156.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, IKEDA K, HORIUCHI S, ZHAO H, ABRAHAM EC: Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses. Biochem. Biophys. Res. Commun. (1997) 241(2):352–354.
   PubMed Web of Science ®Google Scholar
• CHELLAN P, NAGARAJ RH: Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch. Biochem. Biophys. (1999) 368(1):98–104.
   PubMed Web of Science ®Google Scholar
• AHMED MU, BRINKMANN FRYE E, DEGENHARDT TP, THORPE SR, BAYNES JW: N-epsilon-(carboxyethyfllysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. .1. (1997) 324( Pt 2):565–570.
   Google Scholar
• SAXENA P, SAXENA AK, CUI XL, OBRENOVICH M, GUDIPATY K, MONNIER VM: Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: possible role of advanced glycation end products. Invest. Oplithaknol. Vis. Sci. (2000) 41(6):1473–1481.
   PubMed Web of Science ®Google Scholar
• SEBAG J: Age-related changes in human vitreous structure. Craefes Arch. Gin. Exp. Ophthalmol. (1987) 225(2):89–93.
   PubMed Web of Science ®Google Scholar
• STITT AW, MOORE JE, SHARKEY JA et al: Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. Invest. OphthaImol. Vis. Sci. (1998) 39(13):2517–2523.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-THORIN JC: The cornea in diabetes mellitus. mt. Ophthaknot Clin. (1998) 38(2):19–36.
   PubMedGoogle Scholar
• KAJI Y, MSUI T, OSHIKA T et al.: Advanced glycation end products in diabetic corneas. Invest. OphthaImol. Vis. Sci. (2000) 41(2):362–368.
   PubMed Web of Science ®Google Scholar
• MALIK NS, MOSS SJ, AHMED N, FURTH AJ, WALL RS, MEEK KM: Ageing of the human corneal stroma: structural and biochemical changes. Biochim. Biophys. Acta (1992) 1138(3):222–228.
   PubMed Web of Science ®Google Scholar
• MALIK NS, MEEK KM: The inhibition of sugar-induced structural alterations in collagen by aspirin and other compounds. Biochem. Biophys. Res. Commun. (1994) 199(2):683–686.
   PubMed Web of Science ®Google Scholar
• SPOERL E, SEILER T: Techniques for stiffening the cornea. J. Refract. Sing. (1999) 15(6):711–713.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M, VLASSARA H, KOONEY A, ULRICH P, CERAMI A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science (1986) 232(4758):1629–1632.
   PubMed Web of Science ®Google Scholar
• EDELSTEIN D, BROWNLEE M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia (1992) 35(1):96–97.
   PubMed Web of Science ®Google Scholar
• SOULIS-LIPAROTA T, COOPER ME, DUNLOP M, JERUMS G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia (1995) 38(4):387–394.
   PubMed Web of Science ®Google Scholar
• VASAN S, FOILES PG, FOUNDS HW: Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin. Investig. Drugs (2001) 10(11):1977–1987.
   PubMed Web of Science ®Google Scholar
• JIANMONGKOL S, VULETICH JL, BENDER AT, DEMADY DR, OSAWA Y: Aminoguanidine-mediated inactivation and alteration of neuronal nitric-oxide synthase. J. Biol. Chem. (2000) 275(18):13370–13376.
   PubMed Web of Science ®Google Scholar
• FORBES JM, SOULIS T, THALLAS V et al.: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia (2001) 44(1):108–114.
   PubMed Web of Science ®Google Scholar
• KHALIFAH RG, BAYNES JW, HUDSON BG: Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. (1999) 257(2):251–258.
   PubMed Web of Science ®Google Scholar
• NAKAMURA S, MAKITA Z, ISHIKAWA S et al.: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes (1997) 46(5):895–899.
   PubMed Web of Science ®Google Scholar
• NINOMIYA T et aL: EF-6555, a novel AGE production inhibitor, prevents progression of diabetic retinopathy in STZ-induced diabetic rats. Diabetes (2001) 50\(Suppl. 2):Abs 724P
   Google Scholar
• WOLFFENBUTTEL BH, BOULANGER CM, CRIJNS FR et al.: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. USA (1998) 95(8):4630–4634.
   PubMed Web of Science ®Google Scholar
• VASAN S, ZHANG X, ZHANG X et al.: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 382(6588):275–278.
   PubMed Web of Science ®Google Scholar
• COHEN MP, MASSON N, HUD E, ZIYADEH F, HAN DC, CLEMENTS RS: Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse. Exp. Nephrol. (2000) 8(3):135–143.
   PubMedGoogle Scholar
• SCHMIDT AM, STERN DM: RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol. Metab. (2000) 11(9):368–375.
   PubMed Web of Science ®Google Scholar
• LI YM, TAN AX, VLASSARA H: Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat. Med. (1995) 1(10):1057–1061.
   PubMed Web of Science ®Google Scholar
• COOPER ME, THALLAS V, FORBES J et al.: The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia (2000) 43(5):660–664.
   PubMed Web of Science ®Google Scholar
• ASIF M, EGAN J, VASAN S et al.: An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. USA (2000) 97(6):2809–2813.
   PubMed Web of Science ®Google Scholar
• OLDFIELD MD, BACH LA, FORBES JM et al.: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). I. Gin. Invest. (2001) 108(12):1853–1863.
   PubMed Web of Science ®Google Scholar
• VOZIYAN PA, METZ TO, BAYNES JW, HUDSON BG: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. I Biol. Chem. (2002) 277(5):3397–3403.
   Web of Science ®Google Scholar
• PRICE DL, RHETT PM, THORPE SR, BAYNES JW: Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. (2001) 276(52):48967–48972.
   PubMed Web of Science ®Google Scholar
• ONORATO JM, JENKINS AJ, THORPE SR, BAYNES JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. Biol. Chem. (2000) 275(28):21177–21184.
   Google Scholar
• DEGENHARDT 11), ALDERSON NL, ARRINGTON DD et al.: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. (2002) 61(3):939–950.
   Google Scholar